



## Oncternal Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update

October 31, 2019

SAN DIEGO--(BUSINESS WIRE)--Oct. 31, 2019-- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2019 financial results after the U.S. financial markets close on Thursday, November 7, 2019. Oncternal's management will host a webcast and conference call at 2:00 p.m. PST (5:00 p.m. EST) to discuss the Company's financial results and provide a comprehensive business update.

The live webcast of the call will be available online via a link from the [investor relations page](#) of the Company's website at [www.oncternal.com](http://www.oncternal.com), and the call will be archived there for at least 30 days.

### About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The pipeline includes [cirtuzumab](#), an investigational monoclonal antibody designed to inhibit the ROR1 receptor, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), and [TK216](#), an investigational small-molecule compound that is designed to inhibit E26 transformation specific (ETS) family oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program to develop a [CAR-T](#) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at [www.oncternal.com](http://www.oncternal.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191031005152/en/>

Source: Oncternal Therapeutics, Inc.

#### Investors

Richard Vincent  
858-434-1113  
[rvincent@oncternal.com](mailto:rvincent@oncternal.com)

#### Media

Jason Spark  
619-849-6005  
[jason@canalecomm.com](mailto:jason@canalecomm.com)